GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 27 Feb 2015.
Cyclin-dependent kinase 9
TAK, CDK9, Cyclin-Dependent Kinase 9
The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2, and known as important cell cycle regulators. This kinase was found to be a component of the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. This protein forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. HIV-1 Tat protein was found to interact with this protein and cyclin T, which suggested a possible involvement of this protein in AIDS. [provided by RefSeq, Jul 2008] (from
NCBI)
Top mentioned proteins:
PCNA, POLYMERASE, CAN, V1a, HAD
Papers using
TAK
antibodies
Identification of the vesicular nucleotide transporter (VNUT) in taste cells.
Supplier
In PLoS ONE, 2008
... Slices containing vallate taste buds were mounted on a glass coverslip coated with Cell-Tak (Becton Dickinson, Franklin Lakes, NJ, USA), ...
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
Supplier
In Retrovirology, 1995
... Anti-myc, anti-HA, anti-CycT1, anti-Cdk9, and anti-Ub antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) ...
Papers on
TAK
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
New
London, United Kingdom. In Aliment Pharmacol Ther, 23 Mar 2015
BACKGROUND: TAK-438 (vonoprazan) is a potassium-competitive acid blocker that reversibly inhibits gastric H(+) , K(+) -ATPase.
Antileishmanial Effect of 18β-Glycyrrhetinic Acid is Mediated by TLR Dependent Canonical and Noncanonical p38 Activation.
New
Calcutta, India. In Antimicrob Agents Chemother, 17 Mar 2015
Further upstream signaling evaluation by way of phosphorylation kinetics as well as transfection studies with DN constructs identified TGFβ-activated kinase (TAK)1, MyD88, IL-1R-activated kinase (IRAK) 1 and TNF receptor-associated factor (TRAF) 6 as important contributors for GRA- mediated macrophage activation.
Beta-arrestin 1 is involved in the catabolic response stimulated by hyaluronan degradation in mouse chondrocytes.
New
Messina, Italy. In Cell Tissue Res, 13 Mar 2015
Stimulation of both receptors induces nuclear factor kappaB (NF-kB) activation that, through transforming-growth-factor-activated-kinase-1 (TAK-1), in turn stimulates the inflammatory mediators of transcription.
Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5.
New
Impact
Paris, France. In J Clin Oncol, 26 Feb 2015
PURPOSE: Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor.
GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo.
New
Copenhagen, Denmark. In Mol Metab, 31 Jan 2015
In phase-II studies the GPR40 agonist TAK-875 decreased blood glucose but surprisingly without stimulating incretins.
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
New
Impact
San Diego, United States. In Nature, Oct 2014
TAK-875, or fasiglifam, is an orally available, potent and selective partial agonist of hGPR40 receptor, which reached phase III clinical trials for the potential treatment of type-2 diabetes mellitus.
Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
Review
New
Philadelphia, United States. In Pharmacotherapy, Jun 2014
Other FXa inhibitors have not been studied in the long-term management of ACS (e.g., otamixaban), are not currently being studied in ongoing phase III trials (e.g., TAK-442), or have been discontinued by the manufacturer (e.g., darexaban).
Recent advances in Takayasu arteritis.
Review
New
Kyoto, Japan. In Int J Rheum Dis, Mar 2014
Takayasu arteritis (TAK) is a relatively rare systemic vasculitis mainly affecting the aorta and its large branches.
Molecular docking approaches in identification of High affinity inhibitors of Human SMO receptor.
Indore, India. In Bioinformation, 2013
Present study identified the binding affinities of eight established inhibitors viz., Cyclopamine, Saridegib, Itraconazole, LDE-225, TAK-441, BMS-833923 (XL139), PF-04449913 and Vismodegib targeting SMO receptor - a candidate protein involved in hedgehog pathway and sought to identify the best amongst the established inhibitors through by molecular docking.
Regulation of CDK9 activity by phosphorylation and dephosphorylation.
Review
Washington, D.C., United States. In Biomed Res Int, 2013
HIV-1 transcription is regulated by CDK9/cyclin T1, which, unlike a typical cell cycle-dependent kinase, is regulated by associating with 7SK small nuclear ribonuclear protein complex (snRNP).
Physiology and therapeutics of the free fatty acid receptor GPR40.
Review
Auburn, United States. In Prog Mol Biol Transl Sci, 2013
Recently, one of these ligands, TAK-875, has been successfully tested in phase II clinical trials with reduced risk of hypoglycemia.
Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
Review
Kurashiki, Japan. In Expert Opin Pharmacother, 2013
AREAS COVERED: This review is based on a PubMed search for all articles on fasiglifam and TAK-875.
HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia.
Impact
Boulder, United States. In Cell, 2013
HIF1A induces binding of CDK8-Mediator and the super elongation complex (SEC), containing AFF4 and CDK9, to alleviate RNAPII pausing.
The super elongation complex (SEC) family in transcriptional control.
Impact
GeneRIF
Kansas City, United States. In Nat Rev Mol Cell Biol, 2012
Studies indicate that the super elongation complex (SEC) consisting of ELL, P-TEFb (CDK9) and MLL required for rapid transcriptional induction in the presence or absence of paused RNA polymerase II (Pol II).
Separate domains of fission yeast Cdk9 (P-TEFb) are required for capping enzyme recruitment and primed (Ser7-phosphorylated) Rpb1 carboxyl-terminal domain substrate recognition.
GeneRIF
New York City, United States. In Mol Cell Biol, 2012
a Cdk9 carboxyl-terminal extension, distinct from the catalytic domain, mediates binding to both Pcm1 and the Pol II carboxyl-terminal domain
Phosphorylation by cyclin-dependent kinase-9 controls ubiquitin-conjugating enzyme-2A function.
GeneRIF
Göttingen, Germany. In Cell Cycle, 2012
CDK9 phosphorylates UBE2A and regulates UBE2A-mediated monoubiquitination of both H2B and PCNA.
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
Impact
Ann Arbor, United States. In Lancet, 2012
We aimed to assess whether selective pharmacological activation of this receptor by TAK-875 in patients with type 2 diabetes mellitus improved glycaemic control without hypoglycaemia risk.
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
GeneRIF
Guangzhou, China. In Clin Cancer Res, 2012
Data show that the cyclin-dependent kinase 7/9 inhibitor (CDK7/9 inhibitor) potently inhibits FIP1L1-PDGFRalpha-positive Bcr-Abl-positive chronic myeloid leukemia (CML) cells.
Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
GeneRIF
Philadelphia, United States. In Cell Cycle, 2012
siRNA-mediated inhibition of Cdk9 caused a shift from G 0/G 1 to G 2/M phase in human PC3 prostate cancer cell line.
RNAP II CTD phosphorylated on threonine-4 is required for histone mRNA 3' end processing.
Impact
New York City, United States. In Science, 2011
Like Ser(2), Thr(4) phosphorylation requires the CTD kinase CDK9 and is evolutionarily conserved from yeast to human.
